Multiple Myeloma

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.

The EMA's CHMP has recommended the approval of subcutaneous daratumumab plus VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Japan’s Ministry of Health, Labour, and Welfare has accepted the NDA for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma.

The FDA has granted regenerative medicine advanced therapy designation to P-BCMA-ALL01 for relapsed/refractory multiple myeloma.

China’s NMPA granted breakthrough therapy designation to belantamab mafodotin plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

Findings from a molecular analysis of the CoMMpass study identified copy number and expression subtypes of high-risk, newly diagnosed multiple myeloma.

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

Sagar Lonial, MD, FACP, discusses how genetic data from the CoMMpass trial continue to affect the understanding of multiple myeloma.

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status.

The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.

Bertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.